How The Travere Therapeutics (TVTX) Story Is Shifting After FSGS Approval And Split Analyst Views [Yahoo! Finance]
A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI's Landmark FDA Approval For FSGS [Yahoo! Finance]
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Travere Therapeutics (TVTX) was upgraded by Piper Sandler from "neutral" to "overweight". They now have a $49.00 price target on the stock.